Skip to main content
Fig. 3 | Clinical and Translational Allergy

Fig. 3

From: Effectiveness of omalizumab in patients with severe allergic asthma with and without chronic rhinosinusitis with nasal polyps: a PROXIMA study post hoc analysis

Fig. 3

The median number of annual exacerbations in the year prior to initiating omalizumab treatment (baseline) and during 12 months’ treatment with omalizumab, and change from baseline, in patients with with severe allergic asthma with chronic rhinosinusitis with nasal polyps (CRSwNP) or without CRSwNP (No CRSwNP). The p-values within cohorts were calculated using a signed rank test and p-values for comparisons between cohorts were calculated using an ANCOVA model on ranks

Back to article page